Retatrutide vs Tirzepatide (Mounjaro): 28.7% vs 20.9% (2026 Data)

Introduction

Two drugs from the same company. Similar mechanisms. Very different results — and very different timelines.

Tirzepatide (Zepbound for weight loss, Mounjaro for diabetes) achieved 22.5% average weight loss in SURMOUNT-1, the Phase 3 trial that earned its FDA approval. It's available now by prescription. Retatrutide, Eli Lilly's next-generation triple agonist, achieved 28.3–28.7% across two completed Phase 3 trials. It won't be available by prescription until 2027–2028 at the earliest.

The efficacy gap is real and meaningful. But for most people reading this, tirzepatide is the only practical option today — and the evidence for starting now rather than waiting is stronger than the 6-percentage-point efficacy difference might suggest.

This comparison covers what each drug actually does, what the trial data shows, how safety profiles compare, and what that gap means in clinical terms.

Quick Comparison

Clinical Trial Results: What the Data Shows

Retatrutide — TRIUMPH Phase 3 Program

Retatrutide has completed two Phase 3 obesity trials with remarkably consistent results across different populations.

TRIUMPH-4 (December 2025)

TRIUMPH-1 (May 21, 2026)

The consistency between TRIUMPH-4 (28.7%) and TRIUMPH-1 (28.3%) — in different populations, different durations — is exactly what the FDA looks for in a robust efficacy package.

Tirzepatide — SURMOUNT-1

What 6 Percentage Points Actually Means

The 5.6-to-6-percentage-point gap between the drugs translates to a meaningful real-world difference for a heavier patient. For someone starting at 300 lbs:

Note: These are separate trials with different populations and durations — not a direct head-to-head comparison. Cross-trial comparisons are approximate.

Whether an additional ~17 lbs is clinically meaningful depends on the individual. For someone at BMI 35 trying to reach BMI 28, tirzepatide may get them there. For someone at BMI 42 whose goal requires surgical-level loss, the difference matters more.

Mechanism: Why Retatrutide Produces More Weight Loss

Both drugs share two of three receptor targets.

Glucagon is what separates these two drugs. Semaglutide (Wegovy) and tirzepatide achieve weight loss almost entirely through appetite suppression — reducing how much you eat. Retatrutide does that, plus activates glucagon receptors that increase how many calories you burn at rest.

That additional energy expenditure mechanism is the primary driver of the 5–6 percentage point efficacy advantage. It also explains retatrutide's unique side effect: dysesthesia (abnormal skin sensations) is seen only in retatrutide users, not tirzepatide or semaglutide users, and is likely related to glucagon receptor activation or its downstream metabolic effects.

Safety and Side Effects

Gastrointestinal Effects

Both drugs cause GI side effects through GLP-1 receptor activation — this is a class effect, not specific to either drug. Effects are typically worst during dose escalation and improve at maintenance dose.

Tirzepatide percentages are approximate from published SURMOUNT-1 data. Retatrutide figures from Lilly TRIUMPH-1 press release (ADA 2026).

Retatrutide has consistently higher GI rates than tirzepatide. This is consistent across trials and appears to be related to the glucagon component's metabolic effects. Most GI effects are mild to moderate and improve after the initial escalation phase.

Dysesthesia: Retatrutide's Unique Side Effect

Dysesthesia — abnormal skin sensations including tingling, numbness, or unusual touch sensitivity — is not reported with tirzepatide or semaglutide. It is unique to retatrutide and presumed to be related to glucagon receptor activation.

The lower dysesthesia rate in TRIUMPH-1 compared to TRIUMPH-4 at the same 12mg dose is noteworthy. The reasons aren't fully understood, but may relate to population differences — TRIUMPH-4 enrolled a more comorbid population with knee osteoarthritis.

For a complete overview of retatrutide's side effect profile, see our complete side effects guide.

Discontinuation Rates

TRIUMPH-1's 11.3% rate is an improvement over TRIUMPH-4's 18.2%, suggesting the general obesity population tolerates retatrutide meaningfully better than the older, more comorbid OA population. Still higher than tirzepatide's 6.2%.

The trade-off: retatrutide produces substantially higher weight loss with a higher discontinuation rate. Tirzepatide produces somewhat lower weight loss with better tolerability.

Availability: The Most Practical Difference

Tirzepatide: Available by prescription today. FDA approved Zepbound (weight loss) in November 2023, Mounjaro (diabetes) in May 2022. Covered by most commercial insurance for diabetes; coverage for obesity-only indication varies. Self-pay approximately $1,060/month.

Retatrutide: Not available. NDA submission expected Q4 2026, FDA review through 2027, earliest commercial launch Q1–Q2 2028. Self-pay price unknown; comparable injectables price at $1,000–1,500/month.

For most patients, the availability gap is the dominant factor in this comparison — not efficacy.

For a full three-way comparison including semaglutide, see our complete GLP-1 comparison.

Who Should Choose What

Start tirzepatide now if:

You need treatment today and can't wait until 2028. You have time-sensitive health goals — surgery preparation, diabetes risk reduction, joint pain. You've tried semaglutide without adequate response; tirzepatide's GIP activation adds a meaningfully different mechanism. You're satisfied with 22–23% average weight loss — for patients at BMI 30–35, this is often sufficient to achieve target outcomes. You want a proven safety profile with 4+ years of real-world data.

Consider waiting for retatrutide if:

You have severe obesity (BMI ≥40) and specifically need maximum pharmacological weight loss. You've already tried tirzepatide and achieved inadequate results — retatrutide's glucagon component offers a genuinely different mechanism. You can realistically wait until 2028 without clinical harm and are willing to accept an investigational drug's residual uncertainty. You're willing to accept a higher side effect burden for higher efficacy.

Sequential approach — most practical for many patients:

Start tirzepatide now. Achieve 20–23% weight loss over 12–18 months. When retatrutide receives FDA approval, reassess: if you've met your clinical goals, stay on tirzepatide. If you need more, consider switching. Switching requires new titration (8–12 weeks), may temporarily restart GI side effects, and will need insurance reauthorization — but the mechanism shift from dual to triple agonism may produce meaningful additional weight loss.

For a complete overview of retatrutide's current trial status and what happens next before FDA approval, see our complete retatrutide guide.

Conclusion

The data is clear: retatrutide produces 28.3–28.7% average weight loss, tirzepatide 22.5%. A 5–6 percentage point difference is real and clinically meaningful at scale — especially for patients with severe obesity who need maximum weight loss.

The practical picture is equally clear: tirzepatide is available today and has been used safely in millions of patients. Retatrutide won't reach pharmacies until 2028 at the earliest.

For 95% of patients who need treatment in 2026 or 2027, tirzepatide is the right choice — not because it's the better drug on efficacy, but because it's the drug that exists right now. Starting treatment today with an effective, approved medication is better than waiting years for something marginally more effective.

Retatrutide becomes the right conversation in 2028, when it's actually available, and specifically for patients who tried tirzepatide with insufficient results or who have severe obesity requiring maximum pharmacological intervention.

Sources

• Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022;387:205-216. (SURMOUNT-1)
• Jastreboff AM, Kaplan LM, Frías JP, et al. "Retatrutide Phase 3 for Obesity: TRIUMPH-4 Results." New England Journal of Medicine, December 2025.
• Eli Lilly press release: TRIUMPH-1 Phase 3 topline results. May 21, 2026.
• Eli Lilly press release: TRIUMPH-1 and TRANSCEND-T2D-1 results presented at ADA 86th Scientific Sessions. June 6, 2026.
• Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine, 2023;389:514-526.
• FDA: Approval of Zepbound (tirzepatide) for weight management. November 8, 2023.